Document and Entity Information - USD ($) $ in Billions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Feb. 12, 2025 |
Jun. 28, 2024 |
|
| Cover [Abstract] | |||
| Entity Registrant Name | The Chemours Company | ||
| Entity Central Index Key | 0001627223 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Large Accelerated Filer | ||
| Entity Small Business | false | ||
| Entity Emerging Growth Company | false | ||
| Document Type | 10-K | ||
| Trading Symbol | CC | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Amendment Flag | false | ||
| Entity Common Stock, Shares Outstanding | 149,440,788 | ||
| Entity Shell Company | false | ||
| Entity File Number | 001-36794 | ||
| Entity Tax Identification Number | 46-4845564 | ||
| Entity Address, Address Line One | 1007 Market Street | ||
| Entity Address, City or Town | Wilmington | ||
| Entity Address, State or Province | DE | ||
| Entity Address, Postal Zip Code | 19801 | ||
| City Area Code | 302 | ||
| Local Phone Number | 773-1000 | ||
| Title of 12(b) Security | Common Stock ($0.01 par value) | ||
| Security Exchange Name | NYSE | ||
| Entity Incorporation, State or Country Code | DE | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Financial Statement Error Correction | true | ||
| Document Financial Statement Restatement Recovery Analysis | false | ||
| Entity Well-known Seasoned Issuer | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Public Float | $ 3.4 | ||
| ICFR Auditor Attestation Flag | true | ||
| Auditor Name | PricewaterhouseCoopers LLP | ||
| Auditor Location | New York, New York | ||
| Auditor Firm ID | 238 | ||
| Documents Incorporated by Reference | Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to its 2025 annual meeting of shareholders (the “2025 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2025 Proxy Statement will be filed with the U. S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. |
||
| Auditor Opinion [Text Block] | Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of The Chemours Company and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, of comprehensive (loss) income, of stockholders' equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO |